Skip to main content
. 2021 Apr 23;2021:5535578. doi: 10.1155/2021/5535578

Figure 1.

Figure 1

Interleukin 6 (IL-6) levels increased in muscle-invasive bladder cancer (MIBC) and promoted cancer progression. (a) IL-6 levels in MIBC tissues and normal urothelium determined by the enzyme-linked immunosorbent assay (ELISA). (b) Immunochemistry results for IL-6 in MIBC tissues and normal urothelium. (c) IL-6 levels in MIBC tissues and recurrent MIBC determined by ELISA. (d) Immunochemistry results for IL-6 in MIBC tissues and recurrent MIBC. (e) Prognosis of patients with high or low IL-6 expression according to TCGA database. (f) MIBC tumor volume with or without IL-6 treatment (n = 10). (g) Tumor weight with or without IL-6 treatment (n = 10). (h) Survival time for mice with MIBC with or without IL-6 treatment (n = 10). Mean ± SD, ∗∗P < 0.01, ∗∗∗P < 0.005, and ∗∗∗∗P < 0.001.